ATOS

Atossa is a clinical-stage biopharma with essentially no commercial revenue — the only sales figure in the data is a stale $1.76K from FY2015, making the 10,384x P/S and the -7,432% gross margin analytically meaningless. The entire value rests on one lead asset, oral (Z)-endoxifen, a SERM/SERD in Phase 2 for ER+/HER2- breast cancer. The 10-K reports genuinely encouraging early neoadjuvant signals — 'one complete response and multiple partial responses,' 'substantial reductions in Ki-67,' and MRI-confirmed tumor shrinkage 'atypical for endocrine therapies' — plus patent protection through November 2038 and optionality into DMD/MAS. But these are early, single-arm, unblinded readouts; the filing itself flags 'any variation between interim or preliminary and final clinical results.' Outcome is binary and, on the provided data, unknowable — the defining trait of an 'avoid.'

The financials describe a company spending into a cash-runway wall. FY2025 net loss widened to -$34.8M (a fifth straight year of deepening losses: -$20.6M → -$27.0M → -$30.1M → -$25.5M → -$34.8M), operating cash flow was -$29.8M, and R&D jumped +50.1% to $21.2M as the program accelerates. Against that burn, cash fell 41.9% to $41.3M — roughly 14–16 months of runway before a raise is required. The balance sheet is otherwise clean (liabilities/equity just 0.21x, current assets $45.6M vs. current liabilities $8.26M), but the accumulated deficit of -$247M and a 93.3% collapse in share count (a reverse split) tell the dilution story: financing this program means more equity issuance, and the market is signalling it.